Opendata, web and dolomites

InSilc SIGNED

InSilc: In-silico trials for drug-eluting BVS design, development and evaluation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "InSilc" data sheet

The following table provides information about the project.

Coordinator
IDRYMA TECHNOLOGIAS KAI EREVNAS 

Organization address
address: N PLASTIRA STR 100
city: IRAKLEIO
postcode: 70013
website: www.forth.gr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Greece [EL]
 Project website https://insilc.eu/
 Total cost 5˙839˙656 €
 EC max contribution 5˙839˙656 € (100%)
 Programme 1. H2020-EU.3.1.5. (Methods and data)
 Code Call H2020-SC1-2017-CNECT-2
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2020-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IDRYMA TECHNOLOGIAS KAI EREVNAS EL (IRAKLEIO) coordinator 822˙365.00
2    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 746˙830.00
3    POLITECNICO DI MILANO IT (MILANO) participant 603˙130.00
4    NATIONAL UNIVERSITY OF IRELAND GALWAY IE (Galway) participant 566˙155.00
5    UNIVERSITY OF LEEDS UK (LEEDS) participant 559˙580.00
6    CBSET, INC US (LEXINGTON) participant 503˙211.00
7    FEOPS NV BE (GENT) participant 409˙330.00
8    ISTRAZIVACKO RAZVOJNI CENTAR ZA BIOINZENJERING BIOIRC DOO RS (KRAGUJEVAC) participant 363˙080.00
9    CONSIGLIO NAZIONALE DELLE RICERCHE IT (ROMA) participant 343˙705.00
10    BOSTON SCIENTIFIC LIMITED IE (GALWAY) participant 305˙580.00
11    PANEPISTIMIO IOANNINON EL (IOANNINA) participant 259˙355.00
12    MEDIOLANUM CARDIO RESEARCH SRL IT (MILANO) participant 259˙330.00
13    THE UNIVERSITY OF SHEFFIELD UK (SHEFFIELD) participant 98˙000.00

Map

 Project objective

The aim of InSilc is to develop an in-silico clinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), by building on the comprehensive biological and biomedical knowledge and advanced modelling approaches to simulate their implantation performance in the individual cardiovascular physiology. The InSilc platform is based on the extension of existing multidisciplinary and multiscale models for simulating the drug-eluting BVS mechanical behaviour, the deployment and degradation, the fluid dynamics in the micro- and macroscale, and the myocardial perfusion, for predicting its interaction with the vascular wall in the short- and medium/long term. InSilc goes beyond the design and development of ISCT and lays on the generation of in-silico models for obtaining quick and informed answers to several “What if” scenarios. “Virtual” patients would be given a “virtual” drug-eluting BVS, for observing the performance of the scaffold, assess and quantify the intended effect, with a deeper understanding than normal trials can provide. By integrating the information obtained from different in-silico predictive models, InSilc will: (i) assist in the development, assessment and optimization of the drug-eluting BVS and deliver accurate and reliable information to the Stent Biomedical Industry, (ii) assist the interventional Cardiologists in improving the surgical process of drug-eluting BVS implantation, support them in the clinical assessment and reduce the complications of suboptimal scaffold performance. By introducing computer simulations for establishing the safety and efficacy of drug-eluting BVS, InSilc aims to lower development costs and shorten time-to-market, reduce, refine, and partially replace human clinical trials through a more effective human clinical trials design, reduce the need for animal testing and result in a significant reduction of the associated direct and indirect costs.

 Publications

year authors and title journal last update
List of publications.
2018 Georgia S. Karanasiou; Nikolaos S. Tachos; Antonios Sakellarios; Claire Conway; Giancarlo Pennati; Lorenza Petrini; Lampros K. Michalis; Elazer R. Edelman; Dimitrios I. Fotiadis
In Silico analysis of stent deployment - effect of stent design
published pages: , ISSN: , DOI: 10.5281/zenodo.2018351
2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 2019-08-07
2019 Sarrami-Foroushani, Ali; Lassila, Toni; Hejazi, Seyed Mostafa; Nagaraja, Sanjoy; Bacon, Andrew; Frangi, Alejandro F.
A computational model for prediction of clot platelet content in flow-diverted intracranial aneurysms
published pages: , ISSN: 0021-9290, DOI: 10.5281/zenodo.2671637
Journal of Biomechanics 2019-08-07
2018 GEORGIA KARANASIOU; GEORGE RIGAS; SAVVAS KYRIAKIDIS; NIKOLAOS TACHOS; ANTONIS SAKELLARIOS; DIMITRIOS FOTIADIS
InSilc: 3D Reconstruction and plaque characterization tool
published pages: , ISSN: , DOI: 10.5281/zenodo.2017989
2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 2019-08-07
2018 Arso M. Vukicevic, Serkan Çimen, Nikola Jagic, Gordana Jovicic, Alejandro F. Frangi, Nenad Filipovic
Three-dimensional reconstruction and NURBS-based structured meshing of coronary arteries from the conventional X-ray angiography projection images
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-018-19440-9
Scientific Reports 8/1 2019-08-07

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INSILC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INSILC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.5.)

EUCANCan (2019)

EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine.

Read More  

iReceptor Plus (2019)

ARCHITECTURE AND TOOLS FOR THE QUERY OF ANTIBODY AND T-CELL RECEPTOR SEQUENCING DATA REPOSITORIES FOR ENABLING IMPROVED PERSONALIZED MEDICINE AND IMMUNOTHERAPY

Read More  

CINECA (2019)

Common Infrastructure for National Cohorts in Europe, Canada, and Africa

Read More